AIM ImmunoTech (NYSEAMERICAN:AIM) Stock Price Down 2.7% – What’s Next?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM)’s share price dropped 2.7% on Monday . The stock traded as low as $0.2410 and last traded at $0.25. 579,959 shares were traded during mid-day trading, a decline of 42% from the average session volume of 1,001,889 shares. The stock had previously closed at $0.2570.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets reduced their price objective on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $9.00.

AIM ImmunoTech Stock Down 2.7%

The firm has a market cap of $3.64 million, a PE ratio of -0.04 and a beta of 1.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.01. The company’s 50-day simple moving average is $0.37 and its two-hundred day simple moving average is $0.70.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter. On average, analysts predict that AIM ImmunoTech Inc. will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in AIM ImmunoTech stock. DRW Securities LLC grew its holdings in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 69,545 shares of the company’s stock after buying an additional 26,254 shares during the quarter. DRW Securities LLC owned approximately 2.12% of AIM ImmunoTech worth $79,000 at the end of the most recent quarter. 12.02% of the stock is owned by hedge funds and other institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.